カテゴリ： GlobalData, ドイツ, 企業調査

Merck KGaA (MRK)-医療機器分野：企業M&A・提携分析

◆英語タイトル：Merck KGaA (MRK) - Medical Equipment - Deals and Alliances Profile
◆商品コード：DATA8011080
◆発行会社（調査会社）：GlobalData
◆発行日：2017年12月21日
◆ページ数：149
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：ドイツ
◆産業分野：医療機器
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Merck KGaA (Merck), a subsidiary of E. Merck KG, is a pharmaceutical and chemical company. It discovers, develops and manufactures prescription drugs to treat cancer, multiple sclerosis, and infertility and over-the-counter products for colds and pain; and develops liquid crystal mixtures, OLED materials and cosmetic active ingredients. The company also provides a wide range of products including lab water systems to gene editing tools, cell lines, antibodies and end-to-end systems. Merck serves healthcare, performance materials and life sciences markets. It has presence in Europe, North America, Asia-Pacific, Latin America and Middle East and Africa. Merck is headquartered in Darmstadt, Hesse, Germany.

Merck KGaA (MRK) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 7
Merck KGaA, Medical Equipment, Deals By Year, 2011 to YTD 2017 8
Merck KGaA, Medical Equipment Deals By Type, 2011 to YTD 2017 9
Merck KGaA, Medical Equipment, Deals By Region, 2011 to YTD 2017 10
Merck KGaA, Medical Equipment, Deals By Market, 2011 to YTD 2017 11
Merck KGaA, Medical Equipment, Deals Summary, 2011 to YTD 2017 12
Merck KGaA, Medical Equipment, Deal Details 15
Asset Purchase 15
Sigma-Aldrich Acquires Duolink Product Portfolio from Olink Bioscience 15
BioReliance To Acquire Rights To Big Blue Colonies and Cell Lines From Agilent Technologies 16
Venture Financing 17
DNA Script Raises USD13.2 Million in Series A Financing 17
SerImmune Raises USD8 Million in Venture Financing 18
Partnerships 19
Sysmex Enters Into Licensing Agreement With Merck Millipore 19
MDxHealth Enters Into Licensing Agreement With Merck For MGMT Diagnostic Test 20
Sigma Aldrich Enters Into Licensing Agreement With HealthLinx 21
Exosome Diagnostics Enters into Agreement with Merck 22
BioMed X Enters into Agreement with Merck 23
HTG Molecular Diagnostics Enters into Agreement with Merck 24
R-Biopharm Enters into Agreement with Merck 25
Emulate Expands Research Agreement with Merck 26
Merck and Pfizer Enters into Agreement with Dako 27
Sigma-Aldrich Enters into Distribution Agreement with LGC 28
Sigma-Aldrich and GenapSys to Co-Market Genius system 29
Merck Serono Enters into Co- Development Agreement with Illumina 30
Abcam Enters into Co-Marketing Agreement with Cell Marque for IVD IHC RabMAb Antibodies 31
Ventana Medical Systems Enters into Co-Development Agreement with Merck Serono for Companion Diagnostic Test 32
True Diagnostics Enters into Co-Marketing Agreement With Merck 33
Sigma-Aldrich Enters Into Distribution Agreement With Biomatrica For Biospecimen Storage Products 34
Firefly BioWorks Enters Into Distribution Agreement With EMD Millipore 35
Life Technologies Enters Into Agreement With Merck Serono To Develop And Commercialize Companion Diagnostics 36
Gyros And EMD Millipore Enter Into Agreement To Develop And Commercialize Immunoassay Kits 37
Luminex Extends Distribution Agreement With EMD Millipore 38
Alchemia Enters Into Collaboration Agreement with Merck Serono 39
GE Healthcare Life Sciences Enters Into Distribution Agreement With Sigma-Aldrich 40
Sigma Life Science Enters Into Distribution Agreement With Olink Bioscience For Duolink Technology 41
EMD Millipore Enters Into Co-Development Agreement With Sistemic For Stem Cell Markers 42
Merck Serono Enters Into Co-Development Agreement With Auxogyn For Early Embryo Viability Assessment Test 43
Sage Labs Enters Into Agreement With Ekam Imaging To Develop Imaging Assays 44
SciFluor Life Sciences Enters Into Distribution Agreement With Sigma-Aldrich For PhenoFluor 45
Little Things Factory Enters Into Distribution Agreement With Sigma-Aldrich For Microreactors 46
Mendor Enters Into Distribution Agreement With Merck Serono 47
Fluxion Biosciences Enters Into Distribution Agreement With EMD Millipore 48
Diffinity Genomics Enters Into Distribution Agreement With Sigma-Aldrich 49
Sigma Life Science Signs An Agreement With Kraig Biocraft Labs 50
Merck Extends Licensing Agreement with Progyny 51
Sigma-Aldrich Enters Into Licensing Agreement With Scripps Research Institute For Research Reagents 52
Cyprotex Enters Into Licensing Agreement With Sigma For Zinc Finger Nuclease Technology 53
Sigma Life Science Enters Into Licensing Agreement With King’s College London 54
Equity Offering 55
KalVista Pharma Raises USD9.1 Million in Private Placement of Shares 55
Debt Offering 56
Merck Raises USD916 Million in Private Placement of 0.75% Bonds Due 2019 56
Merck Raises USD801.4 Million in Private Placement of 0.23% Bonds Due 2017 57
Merck Raises USD629.7 Million in Private Placement of 1.375% Bonds Due 2022 58
Asset Transactions 59
Zydus Healthcare Acquires Six Brands from Merck 59
Honeywell International Acquires Research Chemicals Business from Sigma-Aldrich 60
Acquisition 62
Merck to Acquire Natrix Separations 62
Merck Acquires Sigma-Aldrich for USD17 Billion 63
Sigma-Aldrich Acquires Cell Marque 65
Proxy Labs Acquires MicroSafe Laboratories From Millipore 66
Sigma-Aldrich Completes Acquisition Of BioReliance For US$350 Million 67
EMD Millipore Completes Acquisition Of Amnis For US$103 Million 69
Merck Acquires heipha Dr. Muller And Related Assets From Biotest 71
Sigma-Aldrich Acquires Resource Technology 73
Merck KGaA – Key Competitors 74
Merck KGaA – Key Employees 75
Merck KGaA – Locations And Subsidiaries 76
Head Office 76
Other Locations & Subsidiaries 76
Recent Developments 86
Strategy And Business Planning 86
Sep 28, 2017: Merck On Course To Achieve Objectives for 2018 86
Sep 05, 2017: Merck Prepares Strategic Options for the Consumer Health Business 88
Jul 21, 2017: Merck Opens New Application Laboratory in Shanghai 89
Jun 29, 2017: Merck Expands Packaging Capacity at Swiss Biotech Manufacturing Site of Aubonne 90
Jun 20, 2017: Merck Ventures Creates New Immuno-Oncology Company iOnctura 91
May 16, 2017: Merck: Optimizing the Further Development of the Darmstadt Site 92
Apr 20, 2017: Merck Provides Upgraded Manufacturing Capabilities to BioInvent with Single-use Mobius Bioreactors 93
Jan 17, 2017: Merck Opens Production Facility Exclusively for Meglumine in Spain 94
Oct 13, 2016: Merck Sets its Sights on 2018 and Outlines Future Strategic Roadmap 95
Jun 17, 2016: Merck Family Foundation Established 97
Jun 09, 2016: Consumer Health To Play A Pivotal Role In Merck’s Africa Growth Strategy 98
Financial Announcements 99
Nov 09, 2017: Merck Confirms Outlook for 2017 Despite a Challenging Third Quarter 99
Aug 03, 2017: Q2 2017: Merck Sets Course for Future Growth 101
May 18, 2017: Merck Continues to Grow Profitably in the First Quarter 103
Aug 04, 2016: Merck Lifts Forecast Following Good Second Quarter 105
Mar 08, 2016: Merck Finishes Record Year 2015 Stronger 108
Corporate Communications 110
Dec 15, 2017: Petra Wicklandt Appointed Head of Corporate Affairs at Merck 110
Dec 12, 2017: Allan Gabor Takes Over the Leadership of Merck in China 111
Dec 06, 2017: Merck: Resignation of Managing Director 112
Sep 11, 2017: Merck Names Heidi Fagerholm as New Head of Advanced Technologies 113
Aug 03, 2017: Executive Board Changes at Merck 114
Jul 21, 2017: Merck Opens New Application Laboratory in Shanghai 115
May 12, 2017: Constantin Birnstiel to Become Head of Group Communications at Merck 116
Feb 08, 2017: North American Businesses of Merck Certified as 2017 Top Employer 117
Sep 23, 2016: Merck Appoints Isabel De Paoli as Chief Strategy Officer 118
Jul 15, 2016: Dietmar Eidens Appointed Chief HR Officer of Merck 119
Jun 01, 2016: Merck’s Belen Garijo Receives Prestigious Career Award 120
Apr 14, 2016: Merck Appoints Maya Martinez-Davis as Global Head of Oncology 121
Mar 29, 2016: MilliporeSigma’s CRISPR Epigenetic Activator Named to The Scientist’s Top 10 Innovation List 122
Jan 27, 2016: Merck Announces New Biopharma Heads for North America and China 123
Legal and Regulatory 124
Apr 14, 2016: Merck Responds to Legal Claims in the U.S. 124
Jan 15, 2016: Merck Announces Favorable English Court Ruling on Name Use 125
Product News 126
Dec 02, 2016: Merck Introduces MILLIPLEX High Sensitivity Panel for Faster, More Economical Cytokine Assays 126
Oct 13, 2016: Merck Introduces First Certified Spiking Solution of Heavy Labeled Thyroglobulin Protein 127
Aug 03, 2016: Merck Expands Portfolio of Certified Reference Materials for Applied Diagnostics and Testing 128
May 11, 2016: Merck Expands Popular Line of Guava Flow Cytometers 129
May 09, 2016: Merck Launches First Commercially Available Equine-Specific Multiplex Assay for Protein Biomarkers 130
Apr 14, 2016: Merck Supports Next Generation of Scientists at USA Science & Engineering Festival 131
Mar 07, 2016: Life Science Leader MilliporeSigma Launches New Innovations at Pittcon 2016 132
02/03/2016: Merck Set To Launch New Version Of Fertility Pens 133
Other Significant Developments 134
Jul 12, 2017: Merck Refines Western European Life Science Production Site Network 134
May 18, 2017: Rational Surgical Solutions integrates Merck Manual of Medicine into Surgery CareSite 135
Mar 21, 2017: Merck Accelerator Hits New Peak of Applications 136
Mar 09, 2017: Merck Generates Record Sales and Continues to Grow Profitably in 2016 137
Jan 12, 2017: Merck and Palantir Launch New Healthcare Acceleration Partnership 139
Nov 15, 2016: Merck Raises Profit Forecast for 2016 Following Good Third Quarter 140
Jul 19, 2016: MilliporeSigma Starts Construction on $115 Million Multi-faceted Life Science Campus in Burlington, Massachusetts 142
Jun 30, 2016: Merck Welcomes ZEISS and Hamilton Thorne as New Members of the Global Fertility Alliance 143
May 19, 2016: Merck Increases Sales and Earnings in Q1 Following Sigma-Aldrich Acquisition 144
Apr 29, 2016: Merck Annual General Meeting 2016: CEO Handover After Ten Successful Years 146
Apr 26, 2016: Saviynt Selected by the Life Science Business of Merck KGaA, Darmstadt, Germany to Secure Its Next-Generation SAP and S/4HANA Platform 148
Appendix 149
Methodology 149
About GlobalData 149
Contact Us 149
Disclaimer 149

List of Tables
Merck KGaA, Medical Equipment, Key Facts, 2016 2
Merck KGaA, Medical Equipment, Deals Summary, 2011 to YTD 2017 2
Merck KGaA, Medical Equipment, Deals By Year, 2011 to YTD 2017 8
Merck KGaA, Medical Equipment Deals By Type, 2011 to YTD 2017 9
Merck KGaA, Medical Equipment, Deals By Region, 2011 to YTD 2017 10
Merck KGaA, Deals By Market, 2011 to YTD 2017 11
Merck KGaA, Medical Equipment, Deals Summary, 2011 to YTD 2017 12
Sigma-Aldrich Acquires Duolink Product Portfolio from Olink Bioscience 15
BioReliance To Acquire Rights To Big Blue Colonies and Cell Lines From Agilent Technologies 16
DNA Script Raises USD13.2 Million in Series A Financing 17
SerImmune Raises USD8 Million in Venture Financing 18
Sysmex Enters Into Licensing Agreement With Merck Millipore 19
MDxHealth Enters Into Licensing Agreement With Merck For MGMT Diagnostic Test 20
Sigma Aldrich Enters Into Licensing Agreement With HealthLinx 21
Exosome Diagnostics Enters into Agreement with Merck 22
BioMed X Enters into Agreement with Merck 23
HTG Molecular Diagnostics Enters into Agreement with Merck 24
R-Biopharm Enters into Agreement with Merck 25
Emulate Expands Research Agreement with Merck 26
Merck and Pfizer Enters into Agreement with Dako 27
Sigma-Aldrich Enters into Distribution Agreement with LGC 28
Sigma-Aldrich and GenapSys to Co-Market Genius system 29
Merck Serono Enters into Co- Development Agreement with Illumina 30
Abcam Enters into Co-Marketing Agreement with Cell Marque for IVD IHC RabMAb Antibodies 31
Ventana Medical Systems Enters into Co-Development Agreement with Merck Serono for Companion Diagnostic Test 32
True Diagnostics Enters into Co-Marketing Agreement With Merck 33
Sigma-Aldrich Enters Into Distribution Agreement With Biomatrica For Biospecimen Storage Products 34
Firefly BioWorks Enters Into Distribution Agreement With EMD Millipore 35
Life Technologies Enters Into Agreement With Merck Serono To Develop And Commercialize Companion Diagnostics 36
Gyros And EMD Millipore Enter Into Agreement To Develop And Commercialize Immunoassay Kits 37
Luminex Extends Distribution Agreement With EMD Millipore 38
Alchemia Enters Into Collaboration Agreement with Merck Serono 39
GE Healthcare Life Sciences Enters Into Distribution Agreement With Sigma-Aldrich 40
Sigma Life Science Enters Into Distribution Agreement With Olink Bioscience For Duolink Technology 41
EMD Millipore Enters Into Co-Development Agreement With Sistemic For Stem Cell Markers 42
Merck Serono Enters Into Co-Development Agreement With Auxogyn For Early Embryo Viability Assessment Test 43
Sage Labs Enters Into Agreement With Ekam Imaging To Develop Imaging Assays 44
SciFluor Life Sciences Enters Into Distribution Agreement With Sigma-Aldrich For PhenoFluor 45
Little Things Factory Enters Into Distribution Agreement With Sigma-Aldrich For Microreactors 46
Mendor Enters Into Distribution Agreement With Merck Serono 47
Fluxion Biosciences Enters Into Distribution Agreement With EMD Millipore 48
Diffinity Genomics Enters Into Distribution Agreement With Sigma-Aldrich 49
Sigma Life Science Signs An Agreement With Kraig Biocraft Labs 50
Merck Extends Licensing Agreement with Progyny 51
Sigma-Aldrich Enters Into Licensing Agreement With Scripps Research Institute For Research Reagents 52
Cyprotex Enters Into Licensing Agreement With Sigma For Zinc Finger Nuclease Technology 53
Sigma Life Science Enters Into Licensing Agreement With King's College London 54
KalVista Pharma Raises USD9.1 Million in Private Placement of Shares 55
Merck Raises USD916 Million in Private Placement of 0.75% Bonds Due 2019 56
Merck Raises USD801.4 Million in Private Placement of 0.23% Bonds Due 2017 57
Merck Raises USD629.7 Million in Private Placement of 1.375% Bonds Due 2022 58
Zydus Healthcare Acquires Six Brands from Merck 59
Honeywell International Acquires Research Chemicals Business from Sigma-Aldrich 60
Merck to Acquire Natrix Separations 62
Merck Acquires Sigma-Aldrich for USD17 Billion 63
Sigma-Aldrich Acquires Cell Marque 65
Proxy Labs Acquires MicroSafe Laboratories From Millipore 66
Sigma-Aldrich Completes Acquisition Of BioReliance For US$350 Million 67
EMD Millipore Completes Acquisition Of Amnis For US$103 Million 69
Merck Acquires heipha Dr. Muller And Related Assets From Biotest 71
Sigma-Aldrich Acquires Resource Technology 73
Merck KGaA, Key Competitors 74
Merck KGaA, Key Employees 75
Merck KGaA, Subsidiaries 76

★海外企業調査レポート[Merck KGaA (MRK)-医療機器分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Koki Holdings Co Ltd：企業の戦略的SWOT分析
    Koki Holdings Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Gedeon Richter Plc：戦略・SWOT・企業財務分析
    Gedeon Richter Plc - Strategy, SWOT and Corporate Finance Report Summary Gedeon Richter Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • VQ OrthoCare：企業の戦略的SWOT分析
    VQ OrthoCare - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • CH2M HILL Companies, Ltd.：戦略・SWOT・企業財務分析
    CH2M HILL Companies, Ltd. - Strategy, SWOT and Corporate Finance Report Summary CH2M HILL Companies, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Qatar Electricity & Water Co QPSC：企業の発電所・SWOT分析2018
    Qatar Electricity & Water Co QPSC - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on …
  • Wintac Ltd (524758)：企業の財務・戦略的SWOT分析
    Summary Wintac Ltd (Wintac), formerly Recon Ltd is a manufacturer and marketer of sterile products. The company offers opthalmic products such as anti-glaucoma, anti-cholinergic, artificial tear, NSAID, steroids and combination, anti-infective, decongestant, anti allergic eye drops and nasal drop, a …
  • Keyence Corp (6861)：企業の財務・戦略的SWOT分析
    Keyence Corp (6861) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Acxiom Corporation：企業の戦略・SWOT・財務分析
    Acxiom Corporation - Strategy, SWOT and Corporate Finance Report Summary Acxiom Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • UGI Corp (UGI)：石油・ガス：M&Aディール及び事業提携情報
    Summary UGI Corp (UGI) is a holding company providing energy products and services. Through subsidiaries, the company stores, transports, distributes and markets energy products and related services. It distributes propane and butane both domestically and internationally and provides natural gas and …
  • Hertz Global Holdings Inc：企業の戦略・SWOT・財務情報
    Hertz Global Holdings Inc - Strategy, SWOT and Corporate Finance Report Summary Hertz Global Holdings Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Volt Information Sciences Inc (VOLT)：企業の財務・戦略的SWOT分析
    Volt Information Sciences Inc (VOLT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • GVC Holdings PLC：企業の戦略・SWOT・財務情報
    GVC Holdings PLC - Strategy, SWOT and Corporate Finance Report Summary GVC Holdings PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Intra Energy Corporation Ltd (IEC)：企業の財務・戦略的SWOT分析
    Intra Energy Corporation Ltd (IEC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Shandong Weigao Group Medical Polymer Company Ltd (1066)-医療機器分野：企業M&A・提携分析
    Summary Shandong Weigao Group Medical Polymer Company Ltd (Weigao) researches, develops, manufactures and sells disposable medical consumables, orthopedic materials and blood purification products. Its products include infusion sets, needles, blood bags, heart eluting stents, blood sampling products …
  • Jiangsu Yuyue Medical Equipment & Supply Co Ltd (002223)：医療機器：M&Aディール及び事業提携情報
    Summary Jiangsu Yuyue Medical Equipment & Supply Co Ltd (Jiangsu Yuyue) is a medical device company that manufactures and distributes various medical equipments. The company’s products include electronic blood pressure monitor, air sterilization purifier, X-ray machine, blood glucose meter, temperat …
  • Ostfold Energi AS：企業の戦略的SWOT分析
    Ostfold Energi AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Baloise Holding Ltd (BALN)：企業の財務・戦略的SWOT分析
    Baloise Holding Ltd (BALN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • MetaStat Inc (MTST)：製薬・医療：M&Aディール及び事業提携情報
    Summary MetaStat Inc (MetaStat) is a biotechnology company that discovers and develops personalized diagnostic and therapeutic treatment solutions for cancer patients. The company develops therapeutic product candidates based on novel approach that offers intracellular Mena protein isoforms drugable …
  • Swan Energy Ltd (SWANENERGY)：企業の財務・戦略的SWOT分析
    Summary Swan Energy Ltd (SEL), formerly Swan Mills Ltd is a textile company that manufactures and markets cotton and polyester textile products. The company also operates through its real estate development of residential and commercial complexes and energy businesses. It operates and develops real …
  • Co-Diagnostics Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary Co-Diagnostics Inc (Co-Diagnostics) is a molecular diagnostics company that develops, manufactures and markets a state-of-the-art diagnostics technology. The company’s products include HCV RNA real-time PCR kit, HIV RNA real-time PCR kit, malaria DNA real-time PCR kit, and TB complex DNA kit …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆